TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04655339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral abdominal Lap-TAP
Description: A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral abdominal Lap-TAP
Description: A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
Study: NCT02168569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem™ (Artemether-lumefantrine combination)
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coarsucam™ (Amodiaquine-artesunate combination)
Description: AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
Study: NCT04477473

Intervention type: OTHER
Intervention: Questionnaire-based observational study
Description: Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)
Study: NCT02861534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: 2.5, 5.0, or 10.0 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for vericiguat
Description: 2.5, 5.0, or 10.0 mg orally once daily
Study: NCT02871843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001 dose escalation with TMZ + RT
Description: Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
Study: NCT03863925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target controlled infusion, Schnider model
Description: Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bolus injection of Propofol
Description: Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
Study: NCT02570217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: infants receive non-invasive respiratory support by mean of HHHFNC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: infants receive non-invasive respiratory support by mean of NCPAP
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens
Study: NCT02871843

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose Temozolomide (75 mg/m2)
Description: Oral temozolomide 75 mg/m2 daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ Maintenance
Description: TMZ maintenance at 150-200 mg/m2
Study: NCT03613506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 Mg
Description: Taking captopril 12.5mg b.i.d for two months before radiotherapy.
Study: NCT03969355

Intervention type: OTHER
Intervention: Mortality
Description: Patients who died during PICU stay

Intervention type: OTHER
Intervention: Mortality
Description: Patients who died during PICU stay
Study: NCT03460184

Intervention type: DIAGNOSTIC_TEST
Intervention: G.A Group A:
Description: G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.

Intervention type: DIAGNOSTIC_TEST
Intervention: G.A Group A:
Description: G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.
Study: NCT02215070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
Study: NCT02049489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICT-121 DC vaccine
Description: autologous dendritic cells pulsed with peptide antigens
Study: NCT00802217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide
Description: 5 mg liquid filled softgel capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide
Description: 5 mg x 2 liquid softgel capsules
Study: NCT01707004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens
Study: NCT01707004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens
Study: NCT01707004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03041259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuveinix Low Dose
Description: A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuveinix High Dose
Description: A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
Study: NCT02042976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Study: NCT03684200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copenhagen adductor exercise
Description: The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
Study: NCT02864641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet K
Description: Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
Study: NCT05550129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral tablet
Study: NCT01896895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobulinumtoxinA (Xeomin), 25 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin), 12.5 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin), 35 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin), 35 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IncobotulinumtoxinA (Xeomin), 35 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.
Study: NCT02472756

Intervention type: DRUG
Intervention: Chemotherapy
Description: The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Study: NCT02472756

Intervention type: DRUG
Intervention: Rituximab
Description: The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Study: NCT02248129

Intervention type: DRUG
Intervention: Telmisartan and hydrochlorothiazide
Study: NCT04699994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT therapy
Description: Preoperative FLOT therapy
Study: NCT01195467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada/Raltegravir
Description: All subjects currently on Atripla® will switch to Truvada/Raltegravir
Study: NCT02837432

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone acetate

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone acetate

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT01795924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-616
Description: Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
Study: NCT03886064

Intervention type: OTHER
Group type: OTHER
Intervention: Multi-behavioral intervention
Description: The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
Study: NCT02488785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Self-Care and Education Program
Description: Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
Study: NCT05676671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applications of self-etching adhesives and dental restorations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applications of self-etching adhesives and dental restorations
Study: NCT01730495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
Study: NCT04512937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation surgery
Description: Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
Study: NCT04440293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBAT
Description: The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBAT
Description: The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT
Description: The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT
Description: The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.